Rapport Therapeutics logo

Rapport Therapeutics

RAPP | NASDAQ
Chart Builder DCF Calculator
$24.82
-$1.33 (-5.09%)
At close: Nov 16, 2026, 4:00 PM ET
$24.39
-$0.43 (-1.73%)
After-hours: Nov 16, 2026, 7:30 PM ET
-5.09%

Rating

Updated: Nov 16, 2026
42.3
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #463/1021 (Top 45%)

Key Statistics

Market Data

Market Cap $1.19B
1D Range
24.63 26.14
52W Range
22.50 52.50

Valuation (TTM)

PE -7.83
PB 3.04
EV/EBITDA -5.07

Valuation (NTM)

Forward PE N/A
Forward PEG -0.47
Price Target $70.00
Loading financial charts...

Profile

Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals li...

Sector Healthcare
Industry Biotechnology
Employees 84
IPO Date Jun 7, 2024
Fiscal Year January - December

Latest News

Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update

13 days ago · globenewswire.com

Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update
Rapport Therapeutics to Participate in Upcoming Investor Conferences

14 days ago · globenewswire.com

Rapport Therapeutics to Participate in Upcoming Investor Conferences
Rapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares and Notes, as well as Concurrent Private Placement

15 days ago · globenewswire.com

Rapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares and Notes, as well as Concurrent Private Placement
Rapport Announces Pricing of Underwritten Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes and Concurrent Private Placement

20 days ago · globenewswire.com

Rapport Announces Pricing of Underwritten Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes and Concurrent Private Placement
Rapport Announces Proposed Public Offerings of Common Stock and Convertible Notes as well as Concurrent Private Placement

20 days ago · globenewswire.com

Rapport Announces Proposed Public Offerings of Common Stock and Convertible Notes as well as Concurrent Private Placement
Rapport Therapeutics' RAP-219 Hits Phase II Goals in Bipolar Mania Trial

23 days ago · marketbeat.com

Rapport Therapeutics' RAP-219 Hits Phase II Goals in Bipolar Mania Trial
Rapport Therapeutics, Inc. (RAPP) Discusses Phase II Bipolar Mania Trial Results and Business Update Transcript

27 days ago · seekingalpha.com

Rapport Therapeutics, Inc. (RAPP) Discusses Phase II Bipolar Mania Trial Results and Business Update Transcript
Why Is Rapport Therapeutics Stock Trading Higher Today?

28 days ago · benzinga.com

Why Is Rapport Therapeutics Stock Trading Higher Today?
Inside the $1 Billion Blockbuster Opportunity That Has Rapport Therapeutics Stock Surging

28 days ago · barrons.com

Inside the $1 Billion Blockbuster Opportunity That Has Rapport Therapeutics Stock Surging
Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania

28 days ago · globenewswire.com

Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania

Earnings

Next Earnings
Mar 9, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
6
Consensus
Buy
Price Target
$70.00
Upside
+182.03%
Buy (6)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.